‘If I had known cancer was linked to implants, I would never have gotten them’
Some women have been diagnosed with BIA-ALCL, a rare type of lymphoma. There have been 600 reported cases worldwide, with 17 deaths.
S ézary syndrome (SS) is an aggressive form of cutaneous T cell lymphoma (CTCL) characterized by involvement of both the skin and the blood. The guarded prognosis for SS reflects a lack of reliably effective therapies. SS patients undergoing treatment often experience transient responses and relapses , supporting the hypothesis that relevant biological heterogeneity exists within the malignant cell population of individual patients. Using single-cell RNA sequencing and machine-learning approaches, we defined a model featuring distinct transcriptomic states within SS.
Thymocyte selection associated high mobility group box 1 (Tox1), a transcription factor that is essential to establish the CD4+ lineage, is overexpressed in malignant cells from patients with CTCL. Knockdown of Tox1 leads to decreased malignant cell viability, while treatment with HDAC inhibitors results in normalization of Tox1expression. Another gene which is consistently overexpressed in patient samples is signal transducers and activators of transcription3 (Stat3), a transcription factor essential for the differentiation of Th17 and follicular helper T cells.
Cutaneous T-cell lymphoma (CTCL) is characterized by resistance to apoptosis involving dysregulation of the FAS ligand (FASL) - FAS death receptor pathway. CTCL cells also exhibit constitutively activated STAT proteins, which are known to upregulate and bind DNA methyltransferases (DNMTs). We hypothesized that, like many other tumor suppressor genes, FAS and FASL expression is at least partially regulated by promoter methylation. Earlier, we showed that methotrexate (MTX), a known folate antagonist, acts as a DNA methylation inhibitor via depleting the methyl donor, S-adenosylmethionine (SAM), in CTCL cells.
Thymocyte selection-associated high mobility group box protein (TOX) is highly enriched in the malignant T cells of cutaneous T cell lymphoma (CTCL). Knocking down its expression resulted in efficient eradication of CTCL cells in culture and in mouse models, suggesting TOX is a desirable target for therapeutic development. Here we describe identification of a novel class of small molecules targeting the DNA binding domain of TOX and evaluation of their ability to inhibit growth and survival of CTCL cells.
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL) primarily arising in the skin. Early diagnosis is difficult as the histology overlaps with features of inflammatory skin diseases. Even when the diagnosis is established there are no prognostic markers that predict whether the disease will be aggressive or indolent. Lastly, there are no curative treatments and MF will invariably relapse even after aggressive chemotherapy. The main objective of this study is to address the presence of intratumor heterogeneity in MF.
Mycosis fungoides (MF) and S ézary syndrome (SS) represent common and uncommon entities among primary cutaneous T cell lymphomas (CTCL). TOX is overexpressed in both of these CTCL entities and is correlated with disease severity and prognosis. TOX is a DNA-binding protein, which enables it to regulate the expression of multipl e downstream genes either directly or indirectly, thus supporting the malignant behavior of T cells in ways that are still unclear. Few validated markers exist which can be used to help discriminate early stage MF from benign inflammatory skin conditions.
Cutaneous T cell lymphoma (CTCL) is a devastating malignancy of the skin for which the standard treatments are suboptimal. Immunotherapy is a new treatment paradigm, and two promising agents for CTCL include brentuximab (anti-CD30) and pembrolizumab (anti-PD-1). While clinical trials have shown that many CTCL patients achieve durable responses on these treatments, for unclear reasons about one third of patients experience rapidly progressive disease. Given the potential for negative outcomes and the high costs of immunotherapy, it is critical to find predictive biomarkers that enable stratification of CTCL patients into re...
ICD is a prerequisite for induction of patient-specific protective immunity against tumor antigens. We hypothesize that the efficacy of Extracorporeal photochemotherapy (ECP) in initiating anti-lymphoma tumor specific immunity is traceable to its efficient induction of ICD in cutaneous T cell lymphoma (CTCL) malignant cells following their lethal exposure to photoactivated 8-methoxysporalen (8-MOPA). We tested that premise in a standard animal ICD vaccination assay, in three murine solid tumor models (sB16-OVA melanoma, YUMMER melanoma and MC38 colon cancer).
Alva and Alberta Pilliod testified this week that they used Monsanto's Roundup for 30 years before they both developed non-Hodgkins lymphoma. They say the weedkiller caused it.
Survivals of advanced anaplastic lymphoma kinase (ALK –positive) non-small cell lung cancer (NSCLC) patients have dramatically changed since the development of efficient ALK tyrosine kinase inhibitors (TKi). However, ALK-positive patients seem to relapse more commonly in the central nervous system (CNS), considered as a sanctuary site. Whether brain metastases (BM) or lepto-meningeal disease (LMD), both are associated with very poor prognosis . Though there is evidence of intracranial activity of 1st generation ALK TKi - crizontib to 2nd and next-generations TKi alectinib, ceretinib against BM, few cases report their activity on LMD.